Cargando…
Clearing and replacing tissue-resident myeloid cells with an anti-CD45 antibody–drug conjugate
Tissue-resident myeloid (TRM) cells in adults have highly variable lifespans, and may be derived from early embryonic yolk sac, fetal liver, or bone marrow. Some of these TRM cells are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic ste...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The American Society of Hematology
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690556/ https://www.ncbi.nlm.nih.gov/pubmed/37748049 http://dx.doi.org/10.1182/bloodadvances.2023010561 |